Intersect ENT seeks FDA nod for Resolve steroid-releasing implant

Intersect ENT (NSDQ:XENT) said today that it submitted a New Drug Application to the FDA for its Resolve steroid-releasing implant to treat chronic sinusitis patients with recurrent sinus obstruction.

The Menlo Park, Calif.-based company’s implant can be placed during a routine physician office visit and is designed to be a less invasive treatment option for recurrent ethmoid sinus obstructions, including polyps.

Get the full story at our sister site, Drug Delivery Business News.

The post Intersect ENT seeks FDA nod for Resolve steroid-releasing implant appeared first on MassDevice.

from MassDevice http://ift.tt/2mYcBri